Legal & General Group
AMLX icon

Legal & General Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Legal & General Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
56,477
+704
+1% +$10.9K ﹤0.01% 2196
2026
Q1 		$775K Sell
55,773
-16,839
-23% -$237K ﹤0.01% 2221
2025
Q4 		$877K Buy
72,612
+5,400
+8% +$73.3K ﹤0.01% 2258
2025
Q3 		$913K Buy
67,212
+59,810
+808% +$563K ﹤0.01% 2267
2025
Q2 		$47.4K Buy
+7,402
New +$36K ﹤0.01% 2718
2024
Q2 		– Sell
-32,854
Closed -$93.3K – 3416
2024
Q1 		$93.3K Sell
32,854
-6,812
-17% -$89.1K ﹤0.01% 2740
2023
Q4 		$584K Buy
39,666
+7,564
+24% +$116K ﹤0.01% 2395
2023
Q3 		$588K Buy
32,102
+3,586
+13% +$75.8K ﹤0.01% 2371
2023
Q2 		$615K Buy
28,516
+1,464
+5% +$39.5K ﹤0.01% 2393
2023
Q1 		$794K Buy
27,052
+22,029
+439% +$765K ﹤0.01% 2203
2022
Q4 		$186K Buy
5,023
+1,562
+45% +$55.4K ﹤0.01% 2639
2022
Q3 		$97K Buy
3,461
+2,237
+183% +$55.8K ﹤0.01% 2835
2022
Q2 		$24K Buy
1,224
+319
+35% +$3.79K ﹤0.01% 3168
2022
Q1 		$12K Buy
+905
New +$20.4K ﹤0.01% 3354

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Legal & General Group's AMLX Position: Q2 2026 in Review

Legal & General Group increased its Amylyx Pharmaceuticals (AMLX) stake by 1.3% in Q2 2026, buying an estimated $10.9K and bringing the position to 56,477 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2196.

Legal & General Group first reported a position in AMLX in Q1 2022 and has held it in 14 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Legal & General Group held 56,477 shares of Amylyx Pharmaceuticals worth $1.01M as of Q2 2026.
  • Legal & General Group bought 704 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $10.9K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2196 holding.
  • Legal & General Group first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.